An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:00 AM EDTCompany ParticipantsMark Stolper - Executive VP ...

Prof. Nicolas Barry-Delongchamps, Professor of Urology at Cochin Hospital and Principal Investigator of the VIOLETTE trial, will present the final results and one-year patients follow-up from the ...

At ECR 2026, under the theme "Rays of Knowledge", United Imaging Intelligence (UII) showcased a comprehensive suite of pioneering AI ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

We’re prostate cancer experts. Here are the benefits of quick and targeted MRI scans - Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prosta ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...